Validation of risk scoring system excluding female sex from CHA2DS2-VASc in Japanese patients with nonvalvular atrial fibrillation:Subanalysis of the J-RHYTHM registry

Circulation Journal

Volumn 79, Issue 8, 2015, Pages 1719-1726

  Tomita, Hirofumi ^a   Okumura, Ken ^a   Inoue, Hiroshi ^b   Atarashi, Hirotsugu ^c   Yamashita, Takeshi ^d   Origasa, Hideki ^b   Tsushima, Eiki ^e  

^a HIROSAKI UNIVERSITY   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

^c NIPPON MEDICAL SCHOOL TAMA NAGAYAMA HOSPITAL   (Japan)

^d THE CARDIOVASCULAR INSTITUTE   (Japan)

^e HIROSAKI UNIVERSITY   (Japan)

Author keywords

CHA2DS2 VA score; CHA2DS2 VASc score; Female sex; Nonvalvular atrial fibrillation; Thromboembolism

Indexed keywords

ANTITHROMBOCYTIC AGENT; WARFARIN;

AGED; ARTICLE; ATRIAL FIBRILLATION; C STATISTIC DIFFERENCE; CARDIOVASCULAR PARAMETERS; CHADS2 SCORE; DRUG USE; FEMALE; GENDER; HUMAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MODIFIED CHADS2 SCORE; NET RECLASSIFICATION IMPROVEMENT; PROSPECTIVE STUDY; RISK FACTOR; THROMBOEMBOLISM; VALIDATION PROCESS; ASIAN CONTINENTAL ANCESTRY GROUP; CLINICAL TRIAL; COMPLICATION; JAPAN; REGISTER; RISK ASSESSMENT; SEX DIFFERENCE; VALIDATION STUDY;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; ATRIAL FIBRILLATION; FEMALE; HUMANS; JAPAN; MALE; REGISTRIES; RISK ASSESSMENT; SEX FACTORS; THROMBOEMBOLISM;

EID: 84937842026     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-15-0095     Document Type: Article

References (35)

1. Wang TJ, Massaro JM, Levy D, Vasan RS, Wolf PA, D’Agostino RB, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: The Framingham Heart Study. JAMA 2003; 290: 1049-1056.
2. Fang MC, Singer DE, Chang Y, Hylek EM, Henault LE, Jensvold NG, et al. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: The AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation 2005; 112: 1687-1691.
3. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on Atrial Fibrillation. Chest 2010; 137: 263-272.
4. Tsadok MA, Jackevicius CA, Rahme E, Humphries KH, Behlouli H, Pilote L. Sex differences in stroke risk among older patients with recently diagnosed atrial fibrillation. JAMA 2012; 307: 1952-1958.
5. Friberg L, Benson L, Rosenqvist M, Lip GY. Assessment of female sex as a risk factor in atrial fibrillation in Sweden: Nationwide retrospective cohort study. BMJ 2012; 344: e3522, doi:10.1136/bmj.e3522.
6. Mikkelsen AP, Lindhardsen J, Lip GY, Gislason GH, Torp-Pedersen C, Olesen JB. Female sex as a risk factor for stroke in atrial fibrillation: A nationwide cohort study. J Thromb Haemost 2012; 10: 1745-1751.
7. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation: Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-2747.
8. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, et al. 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 2014; 130: e199-e267, doi:10.1161/CIR.0000000000000041.
9. Hughes M, Lip GY. Stroke and thromboembolism in atrial fibrillation: A systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 2008; 99: 295-304.
10. Pisters R, Lane DA, Marin F, Camm AJ, Lip GY. Stroke and thromboembolism in atrial fibrillation. Circ J 2012; 76: 2289-2304.
11. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-1457.
12. Atrial Fibrillation Investigators. Echocardiographic predictors of stroke in patients with atrial fibrillation: A prospective study of 1066 patients from 3 clinical trials. Arch Intern Med 1998; 158: 1316–1320.
13. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. JAMA 1998; 279: 1273-1277.
14. Ruigomez A, Johansson S, Wallander MA, Edvardsson N, Garcia Rodriguez LA. Risk of cardiovascular and cerebrovascular events after atrial fibrillation diagnosis. Int J Cardiol 2009; 136: 186-192.
15. Van Staa TP, Setakis E, Di Tanna GL, Lane DA, Lip GY. A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice. J Thromb Haemost 2011; 9: 39-48.
16. Verma A, Cairns JA, Mitchell LB, Macle L, Stiell IG, Gladstone D, et al. 2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. Can J Cardiol 2014; 30: 1114-1130.
17. Nakagami H, Yamamoto K, Ikeda U, Mitsuhashi T, Goto T, Shimada K. Mitral regurgitation reduces the risk of stroke in patients with nonrheumatic atrial fibrillation. Am Heart J 1998; 136: 528-532.
18. Inoue H, Atarashi H. Risk factors for thromboembolism in patients with paroxysmal atrial fibrillation. Am J Cardiol 2000; 86: 852-855.
19. Lin LY, Lee CH, Yu CC, Tsai CT, Lai LP, Hwang JJ, et al. Risk factors and incidence of ischemic stroke in Taiwanese with nonvalvular atrial fibrillation: A nation wide database analysis. Atherosclerosis 2011; 217: 292-295.
20. Guo Y, Apostolakis S, Blann AD, Wang H, Zhao X, Zhang Y, et al. Validation of contemporary stroke and bleeding risk stratification scores in non-anticoagulated Chinese patients with atrial fibrillation. Int J Cardiol 2013; 168: 904-909.
21. Siu CW, Lip GY, Lam KF, Tse HF. Risk of stroke and intracranial hemorrhage in 9727 Chinese with atrial fibrillation in Hong Kong. Heart Rhythm 2014; 11: 1401-1408.
22. Inoue H, Atarashi H, Okumura K, Yamashita T, Origasa H, Kumagai N, et al. Impact of gender on the prognosis of patients with nonvalvular atrial fibrillation. Am J Cardiol 2014; 113: 957-962.
23. JCS Joint Working Group. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2013): Digest version. Circ J 2014; 78: 1997-2021.
24. Atarashi H, Inoue H, Okumura K, Yamashita T, Origasa H. Investigation of optimal anticoagulation strategy for stroke prevention in Japanese patients with atrial fibrillation: The J-RHYTHM Registry study design. J Cardiol 2011; 57: 95-99.
25. Atarashi H, Inoue H, Okumura K, Yamashita T, Kumagai N, Origasa H. Present status of anticoagulation treatment in Japanese patients with atrial fibrillation: A report from the J-RHYTHM Registry. Circ J 2011; 75: 1328-1333.
26. J-RHYTHM Registry Investigators. Determinants of warfarin use and international normalized ratio levels in atrial fibrillation patients in Japan: Subanalysis of the J-RHYTHM Registry. Circ J 2011; 75: 2357-2362.
27. Inoue H, Okumura K, Atarashi H, Yamashita T, Origasa H, Kumagai N, et al. Target international normalized ratio values for preventing thromboembolic and hemorrhagic events in Japanese patients with non-valvular atrial fibrillation: Results of the J-RHYTHM Registry. Circ J 2013; 77: 2264-2270.
28. Okumura K, Inoue H, Atarashi H, Yamashita T, Tomita H, Origasa H. Validation of CHA2DS2-VASc and HAS-BLED scores in Japanese patients with nonvalvular atrial fibrillation: An analysis of the J-RHYTHM Registry. Circ J 2014; 78: 1593-1599.
29. Yamashita T, Inoue H, Okumura K, Atarashi H, Origasa H; on behalf of the J-RHYTHM Registry Investigators. Warfarin anticoagulation intensity in Japanese nonvalvular atrial fibrillation patients: A J-RHYTHM Registry analysis. J Cardiol 2015; 65: 175-177.
30. Inoue H, Atarashi H, Okumura K, Yamashita T, Kumagai N, Origasa H. Thromboembolic events in paroxysmal vs. permanent non-valvular atrial fibrillation: Subanalysis of the J-RHYTHM Registry. Circ J 2014; 78: 2388-2393.
31. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-2870.
32. Overvad TF, Rasmussen LH, Skjoth F, Overvad K, Albertsen IE, Lane DA, et al. Female sex as a risk factor for thromboembolism and death in patients with incident atrial fibrillation: The prospective Danish Diet, Cancer and Health study. Thromb Haemost 2014; 112: 789-795.
33. Cove CL, Albert CM, Andreotti F, Badimon L, Van Gelder IC, Hylek EM. Female sex as an independent risk factor for stroke in atrial fibrillation: Possible mechanisms. Thromb Haemost 2014; 111: 385-391.
34. Ho CW, Ho MH, Chan PH, Hai JJ, Cheung E, Yeung CY, et al. Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: Impact of quality of anticoagulation control. Stroke 2015; 46: 23-30.
35. Suzuki S, Yamashita T, Okumura K, Atarashi H, Akao M, Ogawa H, et al. Incidence of ischemic stroke in Japanese patients with atrial fibrillation not receiving anticoagulation therapy. Circ J 2015; 79: 432-438.